JY
CMPX icon

Jeff Yass’s Compass Therapeutics CMPX Stock Holding History

Jeff Yass’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$675K Buy
308,295
+151,270
+96% +$447K ﹤0.01% 9198
2026
Q1 		$831K Buy
157,025
+112,283
+251% +$648K ﹤0.01% 8384
2025
Q4 		$240K Buy
44,742
+24,782
+124% +$114K ﹤0.01% 10463
2025
Q3 		$69.9K Sell
19,960
-107,312
-84% -$339K ﹤0.01% 11740
2025
Q2 		$331K Sell
127,272
-4,225
-3% -$8.71K ﹤0.01% 10115
2025
Q1 		$250K Buy
131,497
+76,882
+141% +$204K ﹤0.01% 10475
2024
Q4 		$79.2K Buy
54,615
+18,578
+52% +$30.9K ﹤0.01% 11472
2024
Q3 		$66.3K Sell
36,037
-14,418
-29% -$18K ﹤0.01% 11263
2024
Q2 		$50.5K Buy
+50,455
New +$73.7K ﹤0.01% 11407
2024
Q1 		– Sell
-65,852
Closed -$103K – 12293
2023
Q4 		$103K Buy
+65,852
New +$114K ﹤0.01% 11312
2023
Q3 		– Sell
-25,507
Closed -$81.1K – 12109
2023
Q2 		$81.1K Sell
25,507
-757,110
-97% -$2.38M ﹤0.01% 11099
2023
Q1 		$2.56M Buy
782,617
+326,936
+72% +$1.28M ﹤0.01% 4642
2022
Q4 		$2.29M Buy
455,681
+435,943
+2,209% +$1.74M ﹤0.01% 4469
2022
Q3 		$45K Buy
+19,738
New +$54.6K ﹤0.01% 12264

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jeff Yass's CMPX Position: Q2 2026 in Review

Jeff Yass increased its Compass Therapeutics (CMPX) stake by 96% in Q2 2026, buying an estimated $447K and bringing the position to 308,295 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #9198.

Jeff Yass first reported a position in CMPX in Q3 2022 and has held it in 14 quarters since. The position peaked at $2.56M in Q1 2023. 213 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Jeff Yass held 308,295 shares of Compass Therapeutics worth $675K as of Q2 2026.
  • Jeff Yass bought 151,270 Compass Therapeutics shares in Q2 2026, an estimated $447K.
  • Compass Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9198 holding.
  • Jeff Yass first reported a position in Compass Therapeutics in Q3 2022 and has held it in 14 quarters since.
  • Jeff Yass's Compass Therapeutics position peaked at $2.56M in Q1 2023.
  • 213 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.